Stroke RSS

Filtered By:
Specialty: Cardiology
Source: Circulation
Therapy: Statin Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 64 results found since Jan 2013.

Eliminating Medication Copayments for Low-income Older Adults at High Cardiovascular Risk: A Randomized Controlled Trial
Conclusions: In low-income adults at high cardiovascular risk, eliminating copayments (average $35 a month) did not improve clinical outcomes or reduce healthcare costs, despite a modest improvement in adherence to medications.PMID:36871215 | DOI:10.1161/CIRCULATIONAHA.123.064188
Source: Circulation - March 5, 2023 Category: Cardiology Authors: David J T Campbell Chad Mitchell Brenda R Hemmelgarn Marcello Tonelli Peter Faris Jianguo Zhang Ross T Tsuyuki Jane Fletcher Flora Au Scott Klarenbach Derek V Exner Braden J Manns Interdisciplinary Chronic Disease Collaboration Source Type: research

Self-management Support Using Advertising Principles for Older Low Income Adults at High Cardiovascular Risk: a Randomized Controlled Trial
Conclusions: In low-income older adults, a tailored SMES program using advertising principles reduced the rate of clinical outcomes compared with usual care, though the mechanisms of improvement are unclear and further studies are required.PMID:36871212 | DOI:10.1161/CIRCULATIONAHA.123.064189
Source: Circulation - March 5, 2023 Category: Cardiology Authors: David J T Campbell Marcello Tonelli Brenda R Hemmelgarn Peter Faris Jianguo Zhang Flora Au Ross T Tsuyuki Chad Mitchell Raj Pannu Tavis Campbell Noah Ivers Jane Fletcher Derek V Exner Braden J Manns Interdisciplinary Chronic Disease Collaboration Source Type: research

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease
CONCLUSIONS: Long-term LDL-C lowering with evolocumab was associated with persistently low rates of adverse events for over >8 years that did not exceed those observed in the original placebo arm during the parent study and led to further reductions in cardiovascular events compared with delayed treatment initiation.PMID:36031810 | DOI:10.1161/CIRCULATIONAHA.122.061620
Source: Circulation - August 29, 2022 Category: Cardiology Authors: Michelle L O'Donoghue Robert P Giugliano Stephen D Wiviott Dan Atar Anthony C Keech Julia F Kuder KyungAh Im Sabina A Murphy Jose H Flores-Arredondo J Antonio G Lopez Mary Elliott-Davey Bei Wang Maria Laura Monsalvo Siddique Abbasi Marc S Sabatine Source Type: research

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
CONCLUSIONS: In patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, MACEs increased across baseline apoB strata. Alirocumab reduced MACEs across all strata of baseline apoB, with larger absolute reductions in patients with higher baseline levels. Lower achieved apoB was associated with lower risk of MACEs, even after accounting for achieved low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol, indicating that apoB provides incremental information. Achievement of an apoB level ≤35 mg/dL may reduce lipoprotein-attributable residual risk after acute coronary syndrom...
Source: Circulation - June 30, 2022 Category: Cardiology Authors: Emil Hagstr öm P Gabriel Steg Michael Szarek Deepak L Bhatt Vera A Bittner Nicolas Danchin Rafael Diaz Shaun G Goodman Robert A Harrington J Wouter Jukema Evangelos Liberopoulos Nikolaus Marx Jennifer McGinniss Garen Manvelian Robert Pordy Michel Scemama Source Type: research

Circulating Metabolome and White Matter Hyperintensities in Females and Males
Conclusions: Circulating metabolomic measures, including multiple lipid measures (e.g., lysophosphatidylcholines, hydroxysphingomyelins, low-density lipoprotein size and composition) and non-lipid metabolites (e.g., hydroxyphenylpyruvate, glucuronate) associate with WMH in a general population of middle-aged and older adults. Some metabolomic measures show marked sex specificities and explain sizable proportion of WMH variance.PMID:35050683 | DOI:10.1161/CIRCULATIONAHA.121.056892
Source: Circulation - January 20, 2022 Category: Cardiology Authors: Eeva Sliz Jean Shin Shahzad Ahmad Dylan M Williams Stefan Frenzel Friederike Gau ß Sarah E Harris Ann-Kristin Henning Maria Del C Valdes Hernandez Yi-Han Hu Beatriz Jim énez Muralidharan Sargurupremraj Carole Sudre Ruiqi Wang Katharina Wittfeld Qiong Ya Source Type: research

Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis
Conclusions: Current cigarette smoking, diabetes mellitus, and hypertension are independently associated with incident ASCVD over 16-year follow-up among those with CAC=0. Family history of premature ASCVD may be associated with ASCVD risk among women only.PMID:34879218 | DOI:10.1161/CIRCULATIONAHA.121.056705
Source: Circulation - December 8, 2021 Category: Cardiology Authors: Mahmoud Al Rifai Michael J Blaha Vijay Nambi Steven J C Shea Erin D Michos Roger S Blumenthal Christie M Ballantyne Moyses Szklo Philip Greenland Michael D Miedema Khurram Nasir Jerome I Rotter Xiuqing Guo Jie Yao Wendy S Post Salim S Virani Source Type: research

Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG
Conclusions: In REDUCE-IT patients with a history of CABG, treatment with icosapent ethyl was associated with significant reductions in first and recurrent ischemic events.PMID:34710343 | DOI:10.1161/CIRCULATIONAHA.121.056290
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Subodh Verma Deepak L Bhatt Ph Gabriel Steg Michael Miller Eliot A Brinton Terry A Jacobson Nitish K Dhingra Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz C Michael Gibson Duane Pinto Robert P Giugliano Matthew J Budoff R Pre Source Type: research

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Conclusions: In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01492361.PMID:34706555 | DOI:10.1161/CIRCULATIONAHA.121.055560
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Arjun Majithia Deepak L Bhatt Allon N Friedman Michael Miller Ph Gabriel Steg Eliot A Brinton Terry A Jacobson Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz Matthew Budoff R Preston Mason Jean-Claude Tardif William E Boden Ch Source Type: research

Pages: 1 2 3 4 5